What to do when nothing else is left to be done - metastatic non-HPV vulvar squamous cell carcinoma with multiple lines of chemotherapy

Mihaela Mărioara Stana, Sandra Deac, Călin Cainap, Patriciu Achimaș-Cadariu, Mădălina Bota, Liliana Resiga, Dan Ștefan Luchian, Ovidiu Vasile Bochiș


Recurrent vulvar squamous cell carcinoma with multiple site metastases is a rare entity – (up to 14.2% of the total number of recurrences), with a poor prognosis (only 15% of the patients alive at 5 years). Due to its “hard to find” character, there are no standardized guidelines available and the treatment is extrapolated from advanced cervical carcinoma, anal carcinoma and other squamous cell carcinomas. Immunotherapy has shown some positive results in vulvar carcinoma with PD-L1 positive, high TMB, high MSI or with MMR deficiency. An alternative for selected cases without therapeutic resources could be the HPV vaccine. We present the case of a 64-year-old woman diagnosed in 2014 with vulvar squamous cell carcinoma stage II for which she underwent radical vulvectomy with bilateral inguinal lymphadenectomy followed by external radiotherapy. In 2019 she developed local recurrence associated with lung, pleural, lymph nodes and subcutaneous metastasis, treated with three lines of chemotherapy: paclitaxel/carboplatin followed by cisplatin/5-fluorouracil and carboplatin/gemcitabine. The patient’s general health status altered progressively, and she died after the 4th cycle of carboplatin/gemcitabine. This case’s management could be a starting point for the vulvar carcinoma cases where the standard therapeutical options do not represent a choice anymore, providing the necessary example on how to approach it.


vulvar squamous cell carcinoma; recurrence; HPV; chemotherapy

Full Text:



Clancy AA, Spaans JN, Weberpals JI. The forgotten woman's cancer: vulvar squamous cell carcinoma (VSCC) and a targeted approach to therapy. Ann Oncol 2016; 27(9):1696-1705. https://doi.org/10.1093/annonc/mdw242

Zobec Logar HB. Long term results of radiotherapy in vulvar cancer patients in Slovenia between 1997-2004. Radiol Oncol 2017; 51(4):447-454. https://doi.org/10.1515/raon-2017-0024

Peri M, Grassadonia A, Iezzi L, et al. A case of stage I vulvar squamous cell carcinoma with early relapse and rapid disease progression. Case Rep Oncol Med 2019; 2019:1018492. https://doi.org/10.1155/2019/1018492 .

Papatheodorou DC, Liakou CG, Kalogerakos K, Dimopoulos JKA, Kalinoglou N. Bilateral breast metastases from vulvar carcinoma: a case report and literature review. Case Rep Obstet Gynecol 2017; https://doi.org/10.1155/2017/1357203

Syed IMJ, Naveed A, Salman F, Faizan M, Mark S. The tell-tale heart: A case of recurrent vulvar carcinoma with cardiac metastasis and review of literature. Gynecol Oncol Rep 2017; (21):20-23. https://doi.org/10.1016/j.gore.2017.06.004

Woelber L, Jaeger A, Prieske K. New treatment standards for vulvar cancer 2020. Curr Opin Obstet Gynecol 2020; 32(1):9-14. https://doi.org/10.1097/GCO.0000000000000595

Rakislova N, Saco A, Sierra A, Del Pino M, Ordi J. Role of Human Papillomavirus in vulvar cancer. Adv Anat Pathol 2017; 24(4):201-214. https://doi.org/10.1097/PAP.0000000000000155

Deppe G, Mert I, Belotte J, Winer IS. Chemotherapy of vulvar cancer: a review. Wien Klin Wochenschr 2013; 125(5-6):119–128. https://doi.org/10.1007/s00508-013-0338-y

NCCN Guidelines Version 2 .2021. Vulvar Cancer (Squamous Cell Carcinoma). Information [https://www.nccn.org/professionals/physician_gls/pdf/vulvar.pdf avalable at 09/30/2021]

Gustafson LW, Gade M, Blaakær J. Vulvar cancer and HPV vaccination in recurrent disease. Clin Case Rep 2014; 2(6):243-246. https://doi.org/10.1002/ccr3.93

DOI: http://dx.doi.org/10.22551/2021.32.0803.10186

Copyright (c) 2021 Mihaela Mărioara Stana, Sandra Deac, Călin Cainap, Patriciu Achimaș-Cadariu, Mădălina Bota, Liliana Resiga, Dan Ștefan Luchian, Ovidiu Vasile Bochiș

Creative Commons License
Archive of Clinical Cases is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.


ISSN: 2360-6975